Liquid biopsy may detect ALK fusions in lung cancer patients

By staff writers

July 28, 2021 -- The use of next-generation sequencing (NGS)-based circulating-tumor DNA (ctDNA) in liquid biopsies may detect novel anaplastic lymphoma kinase fusions in lung cancer patients, according to a study published in Lung Cancer on July 27.

Liquid biopsy also could be used to serially monitor the development of mechanisms of resistance in response to targeted therapy.

The paper was published by Resolution Bioscience, a part of Agilent Technologies, and Memorial Sloan Kettering Cancer Center; the study is part of a multiyear collaboration between the two organizations.

NGS-based circulating-tumor DNA is a noninvasive alternative to tissue-based methodologies such as fluorescence in situ hybridization, immunohistochemistry, and tissue-based NGS.

Thomas Scientific inks distribution deal with Agilent
Scientific products distributor Thomas Scientific has signed a strategic distribution deal with Agilent Technologies that will allow Thomas to offer a...
Agilent launches SARS-CoV-2 antibody immunoassay kit
Agilent Technologies has launched a new immunoassay kit for the detection of SARS-CoV-2 antibodies. The kit represents Agilent's entry into the U.S. SARS-CoV-2...
Agilent updates Visiopharm image analysis software
Agilent Technologies has released an updated version of its Visiopharm image analysis software. The software now incorporates HercepTest monoclonal antibody...
FDA approves Agilent assay for lung cancer
The U.S. Food and Drug Administration (FDA) has cleared Agilent Technologies' companion diagnostic assay for use in guiding immunotherapy treatment in...
Agilent launches liquid chromatography-mass spectrometry system in U.S.
Agilent Technologies has announced the U.S. launch of a new liquid chromatography-mass spectrometry system designed to improve diagnostic workflow in...

Copyright © 2021

Last Updated ls 7/28/2021 2:46:55 PM